Physician profile
Gregory Martinez
NPI 1578931382
$7,676.15
in general payments reported to CMS, 2019-2025
29 companies · $696 in 2025
The $696 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,444 · 2022: $2,465 · 2023: $2,520 · 2024: $551 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,766.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.81 | 2021-2025 | |
| Novo Nordisk INC | $1,233.31 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $922.55 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $798.30 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $483.54 | 2022-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $383.74 | 2021-2023 | Farxiga, Breztri |
| Abbott Laboratories | $345.41 | 2021-2023 | Aveir |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.53 | 2021-2023 | Xifaxan, Cycloset |
| Corcept Therapeutics | $259.27 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $258.03 | 2021-2023 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $252.83 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $239.48 | 2021-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.83 | 2021-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $145.73 | 2022-2023 | |
| Dexcom, INC. | $134.74 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $124.98 | 2025 | Veozah |
| Nestle Healthcare Nutrition INC. | $60.18 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $52.78 | 2022-2023 | Quviviq |
| Mannkind Corporation | $40.31 | 2022 | |
| Stryker Corporation | $39.30 | 2023 | Mako |
| Pfizer INC. | $34.53 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $30.09 | 2023 | Gemtesa |
| Eisai INC. | $22.16 | 2022 | |
| Amarin Pharma, INC. | $20.82 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.55 | 2021 | |
| Exact Sciences Corporation | $13.71 | 2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $13.34 | 2023 | Accrufer |
| Horizon Therapeutics Plc | $11.68 | 2022 | |
| Althera Pharmaceuticals LLC | $11.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.